Nanobiotix
Created in 2003
Trend leader (A+)
Existing signals make this entity one of the most dynamic startupsSocial networks
1,542 3,848 17,426Activities
Technologies
Entity types
Location
60 Rue de Wattignies, 75012 Paris, France
Paris
France
Employees
Scale: 51-200
Estimated: 146
SIREN
447521600Engaged corporates
15
7 10Added in Motherbase
6 years, 6 months ago
nanotech Value proposition
Building new therapies atom by atom.
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanotherapeutics company pioneering new approaches to significantly improve patient outcomes for millions around the world by building new therapies atom by atom.
The Nanobiotix philosophy is one rooted in designing pioneer physical-based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.
The Nanobiotix global development strategy seeks to address the largest market in oncology—patients who receive radiotherapy as part of their treatment—with NBTXR3 (JNJ-1900). As the first product candidate from the company’s nanoradioenhancer platform, NBTXR3 aims to increase the tumor-killing effect of radiotherapy without increasing damage to surrounding healthy tissues and synergize with other anti-cancer therapies such as immune checkpoint inhibitors.
Beyond NBTXR3, the Curadigm Nanoprimer Platform represents the second technology platform from Nanobiotix and the company’s next lever for growth. Curadigm's innovative approach seeks to improve treatment outcomes across several therapeutic classes by optimizing drug bioavailability and efficacy through systemic delivery enhancement.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA. More: www.nanobiotix.com
Read our Social Media Community Guidelines: https://nanobiotix.com/social-community-guidelines/
Nanomedicine, Pharma, Biotechnology, Oncology, Radiotherapy, Immuno-oncology, Nanoparticles, and NanotechnologyOriginal language
Building new therapies atom by atom.
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanotherapeutics company pioneering new approaches to significantly improve patient outcomes for millions around the world by building new therapies atom by atom.
The Nanobiotix philosophy is one rooted in designing pioneer physical-based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.
The Nanobiotix global development strategy seeks to address the largest market in oncology—patients who receive radiotherapy as part of their treatment—with NBTXR3 (JNJ-1900). As the first product candidate from the company’s nanoradioenhancer platform, NBTXR3 aims to increase the tumor-killing effect of radiotherapy without increasing damage to surrounding healthy tissues and synergize with other anti-cancer therapies such as immune checkpoint inhibitors.
Beyond NBTXR3, the Curadigm Nanoprimer Platform represents the second technology platform from Nanobiotix and the company’s next lever for growth. Curadigm's innovative approach seeks to improve treatment outcomes across several therapeutic classes by optimizing drug bioavailability and efficacy through systemic delivery enhancement.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA. More: www.nanobiotix.com
Read our Social Media Community Guidelines: https://nanobiotix.com/social-community-guidelines/
Building new cancer therapies atom by atom | Nanobiotix
Nanobiotix is a biotechnology company pioneering the discovery, development, manufacture, and commercialization of physics-based nanomedicines
https://nanobiotix.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 CCI Paris IdF Chamber of commerce, Government Administration | CCI Paris IdF Chamber of commerce, Government Administration | Other 18 Jul 2024 | | |
 Karista Startup accelerator & VC, Venture Capital and Private Equity Principals | Karista Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 21 Dec 2023 | | |
 Le Figaro Media, Newspaper Publishing | Le Figaro Media, Newspaper Publishing | Other 12 Jul 2023 | | |
 BFM Business Media, Broadcast Media Production and Distribution | BFM Business Media, Broadcast Media Production and Distribution | Other 17 Aug 2020 | | |
 Institut Curie Health, Hospitals and Health Care | Institut Curie Health, Hospitals and Health Care | Not capitalistic Partnership Event 29 Mar 2022 27 Mar 2023 | | |
 Euronext Finance, Financial Services | Euronext Finance, Financial Services | Not capitalistic Not partnership Event 19 Sep 2019 | | |
 Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Not capitalistic Partnership Not event 9 Apr 2021 | | |
 La French Tech Media, Government Administration | La French Tech Media, Government Administration | Not capitalistic Not partnership Event 12 Dec 2020 | | |
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Capitalistic Partnership Not event 26 Jan 2021 | | |
 Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Other 7 Sep 2020 28 Jul 2023 | | |